Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Wall Street
Price Targets
SUPN Price Targets Summary
Supernus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
SUPN
is 41.31 USD
with a low forecast of 38.38 USD and a high forecast of 45.15 USD.
SUPN Last Price Targets
Supernus Pharmaceuticals Inc
The latest public price target was made on Apr 8, 2024 by
Annabel Samimy
from
Stifel Nicolaus
,
who expects
SUPN
stock to
rise by 23%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Annabel Samimy
Stifel Nicolaus
|
38
USD
Upside 23% |
3 weeks ago
Apr 8, 2024
|
Stifel on Supernus Pharmaceuticals (SUPN): 'SPN-830 Approval Delayed Again, but Near-Term Impact Relatively Minor'
StreetInsider
|
Irene Buhalo
Jefferies
|
40
USD
Upside 30% |
3 weeks ago
Apr 8, 2024
|
Jefferies on Supernus (SUPN): 'We expect a -5-10% stock reaction after the FDA's rejection of SPN-830'
StreetInsider
|
Operating Income
Forecast
Operating Income Estimate
Supernus Pharmaceuticals Inc
For the last 8 years the
compound annual growth rate for
Supernus Pharmaceuticals Inc's operating income is
-4%.
The projected
CAGR
for the next 3 years is
129%.
Net Income
Forecast
Net Income Estimate
Supernus Pharmaceuticals Inc
For the last 8 years the
compound annual growth rate for
Supernus Pharmaceuticals Inc's net income is
-26%.
The projected
CAGR
for the next 3 years is
392%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is SUPN's stock price target?
Price Target
41.31
USD
According to Wall Street analysts, the average 1-year price target for
SUPN
is 41.31 USD
with a low forecast of 38.38 USD and a high forecast of 45.15 USD.
What is Supernus Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
5%
For the last 8 years the
compound annual growth rate for
Supernus Pharmaceuticals Inc's revenue is
19%.
The projected
CAGR
for the next 3 years is
5%.
What is Supernus Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
129%
For the last 8 years the
compound annual growth rate for
Supernus Pharmaceuticals Inc's operating income is
-4%.
The projected
CAGR
for the next 3 years is
129%.
What is Supernus Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
392%
For the last 8 years the
compound annual growth rate for
Supernus Pharmaceuticals Inc's net income is
-26%.
The projected
CAGR
for the next 3 years is
392%.
You don't have any saved screeners yet
